

THE UNIVERSITY of EDINBURGH

# Edinburgh Research Explorer

## MEG-Measured High-Frequency Oscillations in Visual Cortex Indicate Circuit Dysfunctions in Local and Large-Scale Networks during Emerging Psychosis

## Citation for published version:

Grent-'t-Jong, T, Gajwani, R, Gross, J, Gumley, AI, Krishnadas, R, Lawrie, S, Schwannauer, M, Schultze-Lutter, F & Uhlhaas, PJ 2020, 'MEG-Measured High-Frequency Oscillations in Visual Cortex Indicate Circuit Dysfunctions in Local and Large-Scale Networks during Emerging Psychosis', *JAMA Psychiatry*. https://doi.org/10.1001/jamapsychiatry.2020.0284

## Digital Object Identifier (DOI):

10.1001/jamapsychiatry.2020.0284

## Link:

Link to publication record in Edinburgh Research Explorer

**Document Version:** Publisher's PDF, also known as Version of record

Published In: JAMA Psychiatry

## General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

## Take down policy

The University of Édinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



## JAMA Psychiatry | Original Investigation

## Association of Magnetoencephalographically Measured High-Frequency Oscillations in Visual Cortex With Circuit Dysfunctions in Local and Large-scale Networks During Emerging Psychosis

Tineke Grent-'t-Jong, PhD; Ruchika Gajwani, PhD; Joachim Gross, PhD; Andrew I. Gumley, PhD; Rajeev Krishnadas, MD, PhD; Stephen M. Lawrie, MD; Matthias Schwannauer, PhD; Frauke Schultze-Lutter, PhD; Peter J. Uhlhaas, PhD

**IMPORTANCE** Psychotic disorders are characterized by impairments in neural oscillations, but the nature of the deficit, the trajectory across illness stages, and functional relevance remain unclear.

**OBJECTIVES** To examine whether changes in spectral power, phase locking, and functional connectivity in visual cortex are present during emerging psychosis and whether these abnormalities are associated with clinical outcomes.

**DESIGN, SETTING, AND PARTICIPANTS** In this cross-sectional study, participants meeting clinical high-risk criteria for psychosis, participants with first-episode psychosis, participants with affective disorders and substance abuse, and a group of control participants were recruited. Participants underwent measurements with magnetoencephalography and magnetic resonance imaging. Data analysis was carried out between 2018 and 2019.

MAIN OUTCOMES AND MEASURES Magnetoencephalographical activity was examined in the 1to 90-Hz frequency range in combination with source reconstruction during a visual grating task. Event-related fields, power modulation, intertrial phase consistency, and connectivity measures in visual and frontal cortices were associated with neuropsychological scores, psychosocial functioning, and clinical symptoms as well as persistence of subthreshold psychotic symptoms at 12 months.

**RESULTS** The study participants included those meeting clinical high-risk criteria for psychosis (n = 119; mean [SD] age, 22 [4.4] years; 32 men), 26 patients with first-episode psychosis (mean [SD] age, 24 [4.2] years; 16 men), 38 participants with affective disorders and substance abuse (mean [SD] age, 23 [4.7] years; 11 men), and 49 control participants (mean age [SD], 23 [3.6] years; 16 men). Clinical high-risk participants and patients with first-episode psychosis were characterized by reduced phase consistency of  $\beta/\gamma$ -band oscillations in visual cortex (d = 0.63/d = 0.93). Moreover, the first-episode psychosis group was also characterized by reduced occipital  $\gamma$ -band power (d = 1.14) and altered visual cortex connectivity (d = 0.74-0.84). Impaired fronto-occipital connectivity was present in both clinical high-risk participants (d = 0.54) and patients with first-episode psychosis (d = 0.84). Importantly, reductions in intertrial phase coherence predicted persistence of subthreshold psychosis in clinical high-risk participants (receiver operating characteristic area under curve = 0.728; 95% CI, 0.612-0.841; P = .001).

**CONCLUSIONS AND RELEVANCE** High-frequency oscillations are impaired in the visual cortex during emerging psychosis and may be linked to behavioral and clinical impairments. Impaired phase consistency of  $\gamma$ -band oscillations was also associated with the persistence of subthreshold psychosis, suggesting that magnetoencephalographical measured neural oscillations could constitute a biomarker for clinical staging of emerging psychosis.

JAMA Psychiatry. 2020;77(8):852-862. doi:10.1001/jamapsychiatry.2020.0284 Published online March 25, 2020. Corrected on May 6, 2020. Supplemental content

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Peter J. Uhlhaas, PhD, Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany (peter.uhlhaas@charite.de).

jamapsychiatry.com

eural oscillations are a crucial aspect of normal brain functioning owing to their role in facilitating communication between neuronal populations,<sup>1</sup> a process that is closely linked to the integrity of sensory and cognitive processes.<sup>2,3</sup> There is emerging evidence that psychotic disorders with pronounced cognitive impairments, such as schizophrenia, involve aberrant neuronal oscillations,<sup>4</sup> but the nature of the impairment, the onset of deficits, and clinical relevance remain unclear.

 $\beta/\gamma$ -Band oscillations<sup>5-7</sup> but also lower frequencies are impaired during sensory<sup>8</sup> and cognitive tasks<sup>9</sup> in schizophrenia.<sup>10,11</sup> During normal brain functioning, inhibition of excitatory pyramidal cells through different classes of aminobutyric acid (GABA)ergic interneurons lead to the emergence of neural oscillations.<sup>12-15</sup> Converging evidence from genetics,<sup>16</sup> postmortem data,<sup>17,18</sup> and brain imaging have<sup>19</sup> highlighted that GAB-Aergic as well as glutamatergic neurotransmission is impaired in schizophrenia, supporting the possibility that measurements with electro/magnetoencephalography (EEG/MEG) could be important for translational research aimed at identifying circuit mechanisms in the disorder.<sup>10</sup>

Critical questions concerning the role of neural oscillations in the pathophysiology of schizophrenia are the onset of abnormalities, the nature of the deficit, and functional relevance. Early signs of psychosis as well as associated cognitive deficits are already present several years prior to the full emergence of schizophrenia,<sup>20</sup> and thus, research efforts have shifted the focus toward identifying circuit abnormalities and biomarkers in participants who are at risk for the development of psychotic disorders that could allow for early intervention and clinical staging.<sup>21,22</sup>

There is only limited evidence available on alterations of neural oscillations in individuals meeting clinical high-risk criteria for psychosis (CHR-P).<sup>23,24</sup> To address this fundamental question, we applied a state-of-the-art MEG approach to examine low-frequency and high-frequency oscillations during a visual paradigm in CHR-P participants, patients with first-episode psychosis (FEP), and participants with substance-related and affective disorders. Magnetoencephalography is characterized by an improved signal-to-noise ratio for measurements of high-frequency oscillations compared with EEG<sup>25,26</sup> and is ideally suited for source reconstruction, allowing the identification of anatomical layout of generators with high spatial resolution.<sup>27</sup>

Based on models of developing psychosis that have highlighted the central role of visual deficits during the early stages of psychosis<sup>28,29</sup> that predict transition to psychosis<sup>30</sup> as well as the importance of high-frequency oscillations for the integrity of visual perception,<sup>1,31,32</sup> we predicted that CHR-P participants would be characterized by a circumscribed dysfunction of  $\beta/\gamma$ -band oscillations in visual cortex that would be linked to clinical outcomes. Specifically, we focused on the persistence of attenuated psychotic symptoms (APS) because there is evidence to suggest that persistent APS are associated with poor outcomes<sup>33</sup> and cognitive deficits in CHR-P populations.<sup>34</sup> Patients with FEP, on the other hand, would involve largescale dysfunctions of induced oscillations and effective connectivity between frontal and visual areas, consistent with a disconnection syndrome.<sup>35,36</sup>

## **Key Points**

**Question** Are high-frequency oscillations in visual cortex impaired during early stages of psychosis?

**Findings** In this cross-sectional study, there were significant impairments in the variability, power, and connectivity of neural oscillations during visual processing in clinical high-risk participants and patients with first-episode psychosis that were associated with impaired functioning and cognitive deficits. Moreover, the increased variability of  $\gamma$ -band oscillations in visual cortex was also associated with the persistence of subthreshold psychotic symptoms in clinical high-risk participants.

Meaning Impaired high-frequency oscillations in visual cortex are an important aspect of circuit dysfunction, which could constitute a biomarker for clinical staging of emerging psychosis.

## Methods

#### Participants

Four groups of participants (total n = 232) were recruited: (1) participants meeting CHR-P criteria (n = 119) from the ongoing Youth Mental Health Risk and Resilience (YouR) Study<sup>37</sup>; (2) 38 participants who did not meet CHR-P criteria (CHR-N) and were characterized by nonpsychotic disorders, such as affective disorders (n = 11), anxiety disorders (n = 16), eating disorders (n = 1), and/or substance abuse (n = 10); (3) 26 patients with FEP (13 antipsychotic-naive); and (4) 49 healthy control individuals (HC) without an axis I diagnosis or family history of psychotic disorders. Data from 10 patients with FEP and 10 HC have been published previously.<sup>38</sup>

The CHR-P status was confirmed by ultrahigh-risk criteria according to the Comprehensive Assessment of At Risk Mental States (CAARMS) interview<sup>39</sup> and the Cognitive Disturbances and Cognitive-Perceptive Basic Symptoms criteria according to the Schizophrenia Proneness Instrument, Adult version (SPI-A)<sup>40</sup> (see Uhlhaas et al<sup>37</sup>). Patients with FEP were assessed with the Structured Clinical Interview for *DSM-IV* (**Table**)<sup>41</sup> and with the Positive and Negative Symptom Scale.<sup>42</sup> For all groups except patients with FEP, neurocognition was assessed with the Brief Assessment of Cognition in Schizophrenia (BACS).<sup>43</sup> The study was approved by the ethical committees of University of Glasgow and the National Health Services Research Ethical Committee Glasgow and Greater Clyde. All participants provided written informed consent.

#### **Clinical Follow-up**

Participants meeting CHR-P and CHR-N criteria were reassessed at 3-, 6-, 9-, 12-, 18-, 24-, 30-, and 36-month intervals to examine persistence of CHR-P criteria and transition to psychosis (eMethods in the Supplement).

#### Stimuli and Task

Participants were presented with 3 blocks of 80 trials, with each trial consisting of a circular sinewave grating that contracted toward central fixation.<sup>44</sup> The task of the participants was to detect and respond by button press to a velocity increase of

jamapsychiatry.com

No. of participants         Ho         Gala         Clos         Jac         Description         Description           Age, (50) y         23 (3.6)         23 (4.7)         22 (4.4)         24 (4.2)         NA         MA           Age, (50) y         23 (3.7)         22 (4.4)         24 (4.2)         NA         MA           Male/Fernal Sees, No. (6 mule)         [12,7]         (22.9)         27/37 (26.9)         16/10 (61.3)         P = .005           BACS, <sup>2</sup> mean (50)         (22.9)         17 (3.0)         16 (3.1)         15 (3.1)         15 (3.0) $F_{2,29} = 1.38$ , (PF best C, P = .0           Token memory         52 (6.7)         0.01 (1.1)         -0.36 (1.3)         NA         NA         NA           Token motor         81 (11.6)         -0.66 (1.1)         -0.83 (1.3)         NA         NA         NA           Symbol coding         74 (1.1.8)         0.00 (1.3)         -0.53 (1.1)         NA         NA         NA           Symbol coding         74 (1.1.8)         0.01 (1.1)         -0.15 (1.2)         NA         NA         NA           Tower of London         10 (1.7)         0.15 (1.3)         -0.21 (1.5)         NA         NA         NA           Composite score         304 (24.2)	Demographic	нс	CHP-N	СНР-Р	FFD	Group effect <sup>a</sup>	Pairwise comparisons
And Constraint         Display         Display <thdisplay< th="">         Display         <thdisplay< th=""></thdisplay<></thdisplay<>	No. of participants	49	38	119	26	NA	NA
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		23 (3.6)	23 (4 7)	22 (4 4)	24 (4 2)	ΝΔ	NΔ
Education, mean (SD), y         17 (3.0)         16 (3.5)         15 (3.1)         15 (3.0) $F_{abs} = 3.5$ , CRP to HCP = 03           BACS, "mean (SD)         Verbal memory         52 (8.7)         0.01 (1.1)         -0.36 (1.2)         NA         NA         NA           Token motor         81 (1.1.5)         -0.66 (1.1)         -0.99 (1.3)         - $F_{abs} = 1.30$ GRP to HCP = 0.03           Verbal fluency         59 (13.9)         -0.22 (1.0)         0.05 (1.1)         NA         NA         NA           Symbol colling         74 (1.1.8)         0.00 (1.3)         -0.53 (1.1)         NA         NA         NA         NA           Comport London         19 (1.7)         0.15 (1.3)         -0.53 (1.1)         NA $F_{abs} = 0.8$ GRR P HC P = 0.04           Tower of London         19 (1.7)         0.15 (1.3)         -0.53 (1.4)         NA         NA         NA           Composite score         304 (24.2)         -0.15 (1.3)         NA         NA         NA         NA           Unusuat Houge content         NA         1 (1.1)         3 (1.8)         NA         NA         NA           GRADMS, mean (SD)         86 (0.4)         72 (1.2)         NA         NA         NA	Male/female sex, No. (% male)	16/33 (32.7)	11/27 (28.9)	32/87 (26.9)	16/10 (61.5)	$\chi_3^2 = 11.9;$ P = .008	FEP to HC: $P = .016$ ; FEP to CHR-N: $P = .001$ ; EEP to CHR-P: $P = .01$
BACS         Tensen (SD)           Verbal memory         52 (8.7)         0.01 (1.2)         -0.36 (1.3)         NA         NA         NA           Token motor         81 (1.1.6)         -0.66 (1.1)         -0.98 (1.3)         -         Fr <sub>1</sub> , Fr <sub>2</sub> , Fr	Education, mean (SD), y	17 (3.0)	16 (3.5)	15 (3.1)	15 (3.0)	$F_{3,76} = 3.5;$ P = .02	CHR-P to HC: $P = .03$
Veckowsky         S2 (8.7)         0.01 (1.1)         -0.3 (1.3)         NA         NA         NA           Digit sequencing         21 (2.1)         0.14 (1.2)         -0.15 (1.5)         NA         NA         NA           Digit sequencing         21 (2.1)         0.01 (1.2)         -0.98 (1.3)         -         \$	BACS, <sup>b</sup> mean (SD)						
pp Integrating21 (2.1)0.14 (1.2)-0.15 (1.5)NANANAToken motor81 (11.6)-0.66 (1.1)-0.98 (1.3)-0 $F_{p,20} = 3.8$ GR (PA H) (F, P < 0.01 (RP + HC, P < 0.01	Verbal memory	52 (8.7)	0.01 (1.1)	-0.36 (1.3)	NA	NA	NA
Token motor $\$1 (11.6)$ $-0.66 (1.1)$ $-0.98 (1.3)$ $ F_{2,91} = 13.5$ $F^{C} = 0.01$ $F^{C} = 0.02$ $F^{C} = 0.02$ $F^{C} = 0.02$ $F^{C} = 0.02$ 	Digit sequencing	21 (2.1)	0.14 (1.2)	-0.15 (1.5)	NA	NA	NA
vechSp (13) Pollation-0.22 (1.0) Pollation0.05 (1.3)NANANASymbol coding74 (11.8)0.00 (1.3)-0.58 (1.1)NA $P_{p,k} = 6.8$ $P_{p-0.02}$ CiRP - CHR-N: P = . CHR - P CHR-N: P = . CHR - P CHR-N: P = . CHR - P CHR-N: P = . DOATower of London19 (1.7)0.15 (1.3)-0.21 (1.5)NANANANAComposite score306 (24.2)-0.15 (1.2)-0.63 (1.4)NA $P_{p=0.02}$ CHR - P - CHR-N: P = . CHR - P - CHR - N: P = .Unusal thought contentNA1 (1.2)2 (1.9)NANANANAPerceptual abnormalitiesNA1 (1.3)3 (1.6)NANANAPerceptual abnormalitiesNA1 (1.3)3 (1.6)NANANADiorganized speechNA6 (6.1)29 (17.8)NANANANAGAF, mean (SD)& 88 (6.4)70 (12.8)57 (13.4)41 (16.9) $F_{p,q,n} = 29.6$ P < .001	Token motor	81 (11.6)	-0.66 (1.1)	-0.98 (1.3)	-	$F_{2,93} = 13.8;$ P < .001	CHR-N to HC: <i>P</i> = .01; CHR-P - HC: <i>P</i> < .001
Symbol coding         74 (11.8)         0.00 (1.3)         -0.5 8 (1.1)         NA         Fp. a (2.7)         CHR.P CHR.P. Particle           Tower of London         19 (1.7)         0.15 (1.3)         -0.21 (1.5)         NA         NA         NA           Composite score         304 (24.2)         -0.15 (1.2)         -0.63 (1.4)         NA         NA         NA           CAARMS, mean (SD)	Verbal fluency	59 (13.9)	-0.22 (1.0)	0.05 (1.3)	NA	NA	NA
Tower of Londom         19 (1.7)         0.15 (1.3)         -0.21 (1.5)         NA         NA         NA           Composite score         304 (24.2)         -0.15 (1.2)         -0.63 (1.4)         NA $F_{2.99} = 5.6$ CHR.P. HC: P = 0.04           CAARMS, mean (SD)	Symbol coding	74 (11.8)	0.00 (1.3)	-0.58 (1.1)	NA	$F_{2,84} = 6.8;$ P = .002	CHR-P - HC: P = .004; CHR-P - CHR-N: P = .04
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Tower of London	19 (1.7)	0.15 (1.3)	-0.21 (1.5)	NA	NA	NA
CAARMS, mean (SD)         View of the second se	Composite score	304 (24.2)	-0.15 (1.2)	-0.63 (1.4)	NA	$F_{2,93} = 5.8;$ P = .004	CHR-P - HC: <i>P</i> = .004
Unusual throught content         NA         1 (1.2)         2 (1.9)         NA         NA         NA           Nonbizarre ideas         NA         1 (1.1)         3 (1.8)         NA         NA         NA           Perceptual abornalities         NA         1 (0.9)         1 (1.4)         NA         NA         NA           GAF, mean (SD)         88 (6.4)         7 (1.2.8)         5 (1.3.0)         14 (16.5) $\frac{F_{2.75}}{P^2.001} = 167;         All contrasts P < .00;$	CAARMS, mean (SD)						
NA         1 (1.1)         3 (1.8)         NA         NA         NA           Perceptual abnormalities         NA         1 (1.3)         3 (1.6)         NA         NA         NA           Disorganized speech         NA         1 (0.9)         1 (1.4)         NA         NA         NA           GAF, mean (SD)         88 (6.4)         70 (2.8)         57 (13.4)         41 (16.9) $F_{3.75} = 103$ CMR-N-HC:P = 0.37           GF-role, mean (SD)         8.6 (0.8)         8.1 (0.8)         7.4 (1.2)         NA $F_{2.99} = 2.95$ , CMR-N-HC:P = 0.37           GF-social, mean (SD)         8.8 (0.4)         8.2 (0.8)         7.5 (1.2)         NA $F_{2.99} = 5.5$ , CMR-N-HC:P < COUCRR-P to CHR-N:P <	Unusual thought content	NA	1 (1.2)	2 (1.9)	NA	NA	NA
Perceptual abnormalities         NA         1 (1.3)         3 (1.6)         NA         NA         NA           Disorganized speech         NA         1 (0.9)         1 (1.4)         NA         NA         NA           GAF, mean (SD)         88 (6.4)         70 (12.8)         57 (13.4)         41 (16.9) $F_{3,72} = 167$ ; P < .001         All contrasts P < .002 $P < .001$ GF-role, mean (SD)         8.6 (0.8)         8.1 (0.8)         7.4 (1.2)         NA $F_{3,92} = 35.6$ P < .001         CHR-N + HC: P = .037 CHR-P to (HR. P < 000 CHR-P to (HR. P < 000 CHR P to (HR. N < P < 00 CHR P to (HR. N < P < 000 CHR P to (HR. N < P < 00 CHR < CHR N < P < 00 CHR P to (HR. N < P < 00 CHR P to	Nonbizarre ideas	NA	1 (1.1)	3 (1.8)	NA	NA	NA
Disorganized speech         NA         1 (0.9)         1 (1.4)         NA         NA         NA           Total severity score         NA         6 (6.1)         29 (17.8)         NA         NA         NA           GAF, mean (SD)         88 (6.4)         70 (12.8)         57 (13.4)         41 (16.9) $F_{2,70} = 73, contexts P < 0.01$ GF-role, mean (SD)         8.6 (0.8)         8.1 (0.8)         7.4 (1.2)         NA $F_{2,90} = 72, 60, contexts P < 0.01$ GF-social, mean (SD)         8.8 (0.4)         8.2 (0.8)         7.5 (1.2)         NA $F_{2,94} = 59.5, context P < 0.01$ CHR-N + HC, P < 0.03	Perceptual abnormalities	NA	1(1.3)	3 (1.6)	NA	NA	NA
Total severity scoreNA6 (6.1)29 (17.8)NANANANAGAF, mean (SD)88 (6.4)70 (12.8)57 (13.4)41 (16.9) $F_{2,75} = 167$ ; $F^2, 001$ All contrasts $P < .001$ GF-role, mean (SD)8.6 (0.8)8.1 (0.8)7.4 (1.2)NA $F_{2,96} = 29.6$ ; $P < .001$ CHR-N-HC: $P < .03$ CHR-P to HC: $P < .00$ CHR-P to HC: $P < .001$ GF-social, mean (SD)8.8 (0.4)8.2 (0.8)7.5 (1.2)NA $F_{2,96} = 59.5$ ; $P < .001$ CHR-N +C: $P < .001$ CHR-P to HC: $P < .001$ PASS, mean (SD)NANANA18 (7.2)NANANegativeNANANA18 (7.2)NANANegativeNANANANANANACognitiveNANANANANANADetessionNANANANANANADetessionNANANANANANAMedication, No. (%)'NANANANANAAntidepressants0114713NANAAntidepressants0050NANAAntidepressants0114713NANACHR-P cubic/SOUPSCOPER/bothNANAS5 (9/22/24)NANACHR-P cubic/SOUPSCOPER/bothNANAS6 (9/22)NANAAntidepressantsNANA3NANACHR-P cubic/SoupsciresNA </td <td>Disorganized speech</td> <td>NA</td> <td>1 (0.9)</td> <td>1 (1.4)</td> <td>NA</td> <td>NA</td> <td>NA</td>	Disorganized speech	NA	1 (0.9)	1 (1.4)	NA	NA	NA
GAF, mean (SD)         88 (6.4)         70 (12.8)         57 (13.4)         41 (16.9) $F_{2,37,8} = 167;$ $P < .001$ All contrasts $P < .002$ GF-role, mean (SD)         8.6 (0.8)         8.1 (0.8)         7.4 (1.2)         NA $F_{2,39,8} = 29.5;$ P < .001         CHR N - HC: $P = .037CHR P to (HR N: P <GR - social, mean (SD)           GF-social, mean (SD)         8.8 (0.4)         8.2 (0.8)         7.5 (1.2)         NA         F_{2,39,4} = 59.5;P < .001$ CHR N - HC: $P < .000CHR P to (HR N: P <OCHR P to (HR P to HC; P < .000CHR P to (HR P to HC; P < .0001CHR P to (HR P to HC; P < .0001CHR P to (HR P to HC; P < .0001CHR P to (HR P to HC; P < .0001CHR P to (HR P to HC; P < .0001CHR P to (HR P to HC; P < .0001CHR P to (HR P to HC; P < .0001CHR P to (HR P to HC; P < .0001CHR P to (HR P to HC) P < .0011           Negative         NA         NA         NA         NA         NA           Depression         NA         NA         NA         NA         NA           Total score         NA         NA         NA         NA         NA           None         48         27         61         6         NA         NA           Total severity scoreNA6 (6.1)29 (17.8)NANANA$	Total severity score	NA	6 (6.1)	29 (17.8)	NA	NA	NA
GF-role, mean (SD)         8.6 (0.8)         8.1 (0.8)         7.4 (1.2)         NA $F_{2,99} = 29.6; \\ P<.001$ CHR-N + DC (P < 00) CHR-P to CHR-N: P < CHR N + HC: P = 0.31 CHR P to CHR N: P < CHR N + HC: P < 0.31 CHR P to CHR N: P < CHR N + HC: P < 0.31 CHR P to CHR N: P < CHR N + HC: P < 0.31 CHR P to CHR N: P < CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC: P < 0.31 CHR P to CHR N + HC = P < 0.31 CHR P to CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 CHR P CHR N + HC = P < 0.31 C	GAF, mean (SD)	88 (6.4)	70 (12.8)	57 (13.4)	41 (16.9)	$F_{3,75} = 167;$ P < .001	All contrasts P < .001
GF-social, mean (SD)         8.8 (0.4)         8.2 (0.8)         7.5 (1.2)         NA         F2_204 = 59.5, P< < 001         CHR.N + HC: P < 00 CHR.P to CHR.N : <           PAMSS, mean (SD)	GF-role, mean (SD)	8.6 (0.8)	8.1 (0.8)	7.4 (1.2)	NA	$F_{2,99} = 29.6;$ P < .001	CHR-N - HC: <i>P</i> = .037; CHR-P to HC: <i>P</i> < .001; CHR-P to CHR-N: <i>P</i> < .001
PANSS, mean (SD)PositiveNANANANA18 (7.2)NANANegativeNANANANA15 (9.3)NANACognitiveNANANANA20 (9.2)NANACognitiveNANANA20 (9.2)NANAExcitementNANANA9 (4.3)NANADepressionNANANA12 (5.9)NANATotal scoreNANANA74 (28.4)NANAMedication, No. (%) <sup>C</sup> NAMone4827616NANAAntidepressants0114713NANAMod stabilizers00313NANAOther (unknown)1 (0)2 (0)21 (0)5 (0)NANACHR-P categoriesS (9/22/24)NANASPI-A (COGDIS/COPER/both items)NANA30 (4/15/11)NANANAMINI categories1175NANANAMINI categoriesNA1175NANANADepressive/moord disordersNA1110NANANADrug/alcohol abuse/dependenceNA1042NANANADSM-1/V/Structured Clinical Interview1042NA	GF-social, mean (SD)	8.8 (0.4)	8.2 (0.8)	7.5 (1.2)	NA	$F_{2,94} = 59.5,$ P < .001	CHR-N - HC: <i>P</i> < .001; CHR-P to HC: <i>P</i> < .001; CHR-P to CHP-N: <i>P</i> < .001
PositiveNANANANA18 (7.2)NANANegativeNANANANA15 (9.3)NANANegativeNANANANA15 (9.3)NANACognitiveNANANANA20 (9.2)NANAExcitementNANANANA9 (4.3)NANADepressionNANANANA9 (4.3)NANADepressionNANANANA74 (28.4)NANAMedication, No. (%) <sup>c</sup> None4827616NANAAntidepressants0114713NANAMod stabilizers0050NANAOther (unknown)1 (0)2 (0)21 (0)5 (0)NANACHR-P categoriesSPI-A (COGDIS/COPER/both items)NANA89 (87/2)NANANACARMS (APS/vulnerability criteria)NANA55 (9/22/24)NANANAMINI categoriesI75NANANAAndMINI categoriesNA1175NANANADepressive/mood disordersNA1687NANANADisorders/postraumatic stress disorder/postersive-compulsive disorderNA1042NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANA <td< td=""><td>PANSS, mean (SD)</td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	PANSS, mean (SD)						
NegativeNANANANA15 (9.3)NANACognitiveNANANANANANAExcitementNANANANA9 (4.3)NANADepressionNANANANA12 (5.9)NANATotal scoreNANANA74 (28.4)NANAMedication, No. (%)°	Positive	NA	NA	NA	18 (7.2)	NA	NA
CognitiveNANANANA20 (9.2)NANAExcitementNANANANA9 (4.3)NANADepressionNANANANA12 (5.9)NANATotal scoreNANANANA74 (28.4)NANAMedication, No. (%) <sup>c</sup> </td <td>Negative</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>15 (9.3)</td> <td>NA</td> <td>NA</td>	Negative	NA	NA	NA	15 (9.3)	NA	NA
ExcitementNANANANA9 (4.3)NANADepressionNANANANA12 (5.9)NANATotal scoreNANANANA74 (28.4)NANAMedication, No. (%) <sup>c</sup> </td <td>Cognitive</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>20 (9.2)</td> <td>NA</td> <td>NA</td>	Cognitive	NA	NA	NA	20 (9.2)	NA	NA
DepressionNANANANANANANATotal scoreNANANANA74 (28.4)NANAMedication, No. (%) <sup>c</sup> None4827616NANAAntidepressants0114713NANAMood stabilizers0050NANAOther (unknown)1 (0)2 (0)21 (0)5 (0)NANACHR-P categoriesSPI-A (COGDIS/COPER/both items)NANA30 (4/15/11)NANANACARMS (APS/vulnerability criteria)NANA89 (87/2)NANANAMNI categoriesU1175NANANAMINI categoriesNA1175NANANAMoti disordersNA1042NANANADepressive/mood disordersNA1042NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANANASchizophreniaNANANANANANA	Excitement	NA	NA	NA	9 (4.3)	NA	NA
Total scoreNANANA74 (28.4)NANAMedication, No. (%) cMone4827616NANAAntidepressants0114713NANAMood stabilizers0050NANAModo stabilizers00313NANAOther (unknown)1 (0)2 (0)21 (0)5 (0)NANACHR-P categoriesS0NANA30 (4/15/11)NANANACAARMS (APS/vulnerability criteria)NANA89 (87/2)NANANANAMINI categoriesNA1175NANANANAMixety disorders/posttraumatic stress disorder/obsessive-compulsive disorderNA1042NANANADSM-IV/Structured Clinical InterviewNA1042NANANANADSM-IV/Structured Clinical InterviewNANANANANANANASchizophreniaNANANANANANANANA	Depression	NA	NA	NA	12 (5.9)	NA	NA
Medication, No. (%)^cNnNnNnNnNnMedication, No. (%)^c4827616NANAAntidepressants0114713NANAMood stabilizers0050NANAAntipsychotics00313NANAOther (unknown)1 (0)2 (0)21 (0)5 (0)NANACHR-P categoriesSSSSSNANACARMS (APS/vulnerability criteria)NANA89 (87/2)NANANACAARMS plus SPI-A (COGDIS/COPER/bothNANA89 (87/2)NANANACAARMS plus SPI-A (COGDIS/COPER/bothNANAS5 (9/22/24)NANANAMINI categoriesDepressive/mood disordersNA1175NANANAMini tategoriesNA1687NANANADrug/alcohol abuse/dependenceNA1042NANANADrug/alcohol abuse/dependenceNA110NANANADSM-IV/Structured Clinical InterviewSchizophreniaSNANANANASchizophreniform disorderNANANANANANANA	Total score	NA	NA	NA	74 (28.4)	NA	NA
None4827616NANAAntidepressants0114713NANAMood stabilizers0050NANAAntipsychotics00313NANAOther (unknown)1 (0)2 (0)21 (0)5 (0)NANACHR-P categoriesSPI-A (COGDIS/COPER/both items)NANA30 (4/15/11)NANANACARMS (APS/vulnerability criteria)NANA89 (87/2)NANANACARMS Juls SPI-A (COGDIS/COPER/bothNANA89 (87/2)NANANAMINI categoriesII75NANANAMINI categoriesNA1175NANANADepressive/mood disordersNA1687NANANAAnxiety disorders/posttraumatic stress disorder/bassive-compulsive disorderNA1042NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANANANASchizophreniaNANANA3NANA	Medication No (%) <sup>c</sup>						
Antidepressants0114713NANAMood stabilizers0050NANAAntigsychotics00313NANAOther (unknown)1 (0)2 (0)21 (0)5 (0)NANACHR-P categoriesSPI-A (COGDIS/COPER/both items)NANA30 (4/15/11)NANANACARRMS (APS/vulnerability criteria)NANA89 (87/2)NANANACARRMS plus SPI-A (COGDIS/COPER/bothNANA89 (87/2)NANANAMINI categoriesNA1175NANANAMini categoriesNA1687NANANADepressive/mood disordersNA1042NANANADrug/alcohol abuse/dependenceNA110NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANANASchizophreniaNANANANANANA	None	48	27	61	6	NA	NA
MindepressionoAAAAMood stabilizers0050NANAAntipsychotics00313NANAOther (unknown)1 (0)2 (0)21 (0)5 (0)NANACHR-P categoriesSPI-A (COGDIS/COPER/both items)NANA30 (4/15/11)NANANACAARMS (APS/vulnerability criteria)NANA89 (87/2)NANANACAARMS plus SPI-A (COGDIS/COPER/bothNANA89 (87/2)NANANAMINI categoriesIT75NANANAMini categoriesNA1175NANANADrug/alcohol abuse/dependenceNA1042NANANADSM-IV/Structured Clinical InterviewI10NANANASchizophreniaNANANANANANASchizophreniform disorderNANANANANA	Antidepressants	0	11	47	13	NA	NA
Antipact Stabilizer0003101 (NAAntipsychotics00313NANAOther (unknown)1 (0)2 (0)21 (0)5 (0)NANACHR-P categoriesS0 (4/15/11)NANANACAARMS (APS/vulnerability criteria)NANA89 (87/2)NANANACAARMS plus SPI-A (COGDIS/COPER/bothNANA89 (87/2)NANANACAARMS plus SPI-A (COGDIS/COPER/bothNANA55 (9/22/24)NANANACAARMS plus SPI-A (COGDIS/cOPER/bothNANA55 (9/22/24)NANANAMINI categoriesNANADepressive/mood disordersNA1175NANANAAnxiety disorders/posttraumatic stress disorder/obsessive-compulsive disorderNA1042NANADrug/alcohol abuse/dependenceNA110NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANASchizophreniaNANANANA3NANA	Mood stabilizers	0	0	5	0	ΝΔ	NΔ
AntipychologyOOOODDD <t< td=""><td>Antinsychotics</td><td>0</td><td>0</td><td>3</td><td>13</td><td>ΝΔ</td><td>NΔ</td></t<>	Antinsychotics	0	0	3	13	ΝΔ	NΔ
Other (dirkiowir)T (o)T	Other (unknown)	1 (0)	2 (0)	21 (0)	5 (0)	NA	NA
SPI-A (COGDIS/COPER/both items)NANA30 (4/15/11)NANANACAARMS (APS/vulnerability criteria)NANA89 (87/2)NANANACAARMS plus SPI-A (COGDIS/COPER/bothNANA55 (9/22/24)NANANAMINI categoriesDepressive/mood disordersNA1175NANANAAnxiety disorders/posttraumatic stress disorder/obsessive-compulsive disorderNA1687NANANADrug/alcohol abuse/dependenceNA1042NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANANASchizophreniaNANANAANANA	CHP_P categories	1(0)	2 (0)	21(0)	5 (0)	117	
SHA (coord) (corect/both memory)NANANASo (4/15/11)NANANACAARMS (APS/vulnerability criteria)NANANA89 (87/2)NANANACAARMS plus SPI-A (COGDIS/COPER/bothNANAS5 (9/22/24)NANANAMINI categoriesDepressive/mood disordersNA1175NANANAAnxiety disorders/posttraumatic stress disorder/obsessive-compulsive disorderNA1687NANANADrug/alcohol abuse/dependenceNA1042NANANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANANANASchizophreniaNANANAANANANA	SPL A (COCDIS/COPER/both itoms)	ΝΑ	NA	20 (1/15/11)	NA	ΝΔ	ΝΑ
CAARMS (AF) vulnerability citeria)NANANAS3 (S7/2)NANANACAARMS plus SPI-A (COGDIS/COPER/both items)NANAS5 (9/22/24)NANANAMINI categoriesDepressive/mood disordersNA1175NANANAAnxiety disorders/posttraumatic stress disorder/obsessive-compulsive disorderNA1687NANANADrug/alcohol abuse/dependenceNA1042NANANAEating disordersNA110NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANANASchizophreniaNANANANANANA	CAADMS (ADS / wulperability criteria)	NA		30 (4/13/11) 90 (97/2)		NA	
CARRING plus SPI-A (COGDIS/COPER/DOLITNANANAS3 (9/22/24)NANANANAMINI categoriesDepressive/mood disordersNA1175NANANAAnxiety disorders/posttraumatic stress disorder/obsessive-compulsive disorderNA1687NANANADrug/alcohol abuse/dependenceNA1042NANANAEating disordersNA110NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANANASchizophreniaNANANA3NANA		NA		69 (67/2)	NA	NA	NA
Depressive/mood disordersNA1175NANANAAnxiety disorders/posttraumatic stress disorder/obsessive-compulsive disorderNA1687NANANADrug/alcohol abuse/dependenceNA1042NANANAEating disordersNA110NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANANASchizophreniaNANANA3NANA	items)	NA	NA	55 (9/22/24)	NA	NA	NA
Depressive/indod disordersNAII73NANANAAnxiety disorders/posttraumatic stress disorder/obsessive-compulsive disorderNA1687NANANADrug/alcohol abuse/dependenceNA1042NANANAEating disordersNA110NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANANASchizophreniaNANANA3NANA	Depressive/mood disorders	ΝΑ	11	75	NA	NA	ΝΑ
Drug/alcohol abuse/dependenceNA1042NANANAEating disordersNA110NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANA9NANASchizophreniform disorderNANANA3NANA	Anxiety disorders/posttraumatic stress	NA	16	87	NA	NA	NA
Eating disordersNA110NANANADSM-IV/Structured Clinical InterviewSchizophreniaNANANA9NANASchizophreniform disorderNANANA3NANA	Drug/alcohol abuse/dependence	NA	10	42	NA	NA	NA
DSM-IV/Structured Clinical InterviewNANANANA9NANASchizophreniaNANANANANANASchizophreniform disorderNANANANANA	Eating disorders	NA	1	10	NA	NA	NA
SchizophreniaNANANA9NANASchizophreniform disorderNANANA3NANA	DSM-IV/Structured Clinical Interview		-	10			
Schizophreniform disorder         NA         NA         NA         NA         NA	Schizophrenia	NA	NA	NA	9	NA	NA
	Schizophreniform disorder	NA	NA	NA	3	NA	NA
Schizoaffective disorder NA NA NA 1 NA NA	Schizoaffective disorder	NA	NA	NA	1	NA	NA

(continued)

#### Table. Demographics, Clinical Data, and Task Performance (continued)

Demographic	нс	CHR-N	CHR-P	FEP	Group effect <sup>a</sup>	Pairwise comparisons
Psychotic disorder NOS	NA	NA	NA	8	NA	NA
Brief psychotic disorder	NA	NA	NA	1	NA	NA
Mood disorders with psychotic features	NA	NA	NA	4	NA	NA
Trial No., total included (SD)	197 (16.3)	194 (16.2)	185 (26.5)	181 (29.2)	$F_{3,80} = 5.9;$ P = .001	CHR-P to HC: <i>P</i> = .002
Task performance						
Accuracy, % correct (SD)	92.2 (6.9)	92.0 (5.6)	88.0 (9.8)	85.9 (12.8)	$F_{3,79} = 5.5,$ P = .002	CHR-P to HC: P = .01; CHR-P vs CHR-N: P = .01
Reaction time, mean (SD), ms	528 (68.4)	524 (80.1)	545 (84.9)	577 (100.1)	NA	NA
Response variance, <sup>d</sup> mean (SD), ms	151.7 (37.5)	154.3 (34.9)	164.3 (42.2)	179.1 (40.8)	$F_{3,79} = 3.3;$ P = .02	FEP to HC: <i>P</i> = .03

Abbreviations: APS, attenuated psychotic symptoms; BACS, Brief Assessment of Cognition in Schizophrenia; CAARMS, Comprehensive Assessment of At Risk Mental States; CHR-N, clinical high risk negative; CHR-P, clinical high risk positive; COGDIS/COPER, Cognitive Disturbances and Cognitive-Perceptive Basic Symptoms criteria; FEP, first-episode psychosis; GAF, global assessment of functioning; GF, global functioning; HC, healthy control individual; MINI, Mini-International Neuropsychiatric Interview; PANSS, Positive and Negative Symptom Scale; SPI-A, Schizophrenia Proneness Instrument, Adult version. <sup>a</sup> All *F* tests are Welch based; α = .05, 2-sided, 1000 samples bootstrapping, post hoc Games-Howell correction for type I errors.

<sup>b</sup> BACS scores for clinical groups were standardized to control group data, controlled for sex category.

<sup>c</sup> If multiple medications were reported, they were scored separately in the different categories listed.

<sup>d</sup> Response variance equals standard deviation of response times across trials.

#### Figure 1. Paradigm and Task Performance



A, Inward moving grating task: participants report, by button press, the onset of a change in velocity of inward motion of the visual stimulus (correct response window, 200-1200 milliseconds). Feedback on performance was provided on every trial, shortly after the response onset terminated stimulus presentation. B, Histograms of group means and standard errors for accuracy (% correct), mean reaction times (RTs), and behavioral variability (intraindividual standard

deviation of RTs). CHR-N indicates clinical high risk negative; CHR-P, clinical high risk positive; FEP, first-episode psychosis; HC, healthy control individuals.

<sup>a</sup> Indicates significant group differences (Welch *F* tests, α = .05, 2-sided, 1000 samples bootstrapping, Games-Howell corrected for multiple comparisons).

the stimulus, randomly occurring between 750 and 3000 milliseconds (Figure 1).

## Neuroimaging

Magnetoencephalography data were acquired using a 248channel 4D-BTI magnetometer system (MAGNES 3600 WH, 4-dimensional neuroimaging; Bio-Medicine), recorded with 1017.25-Hz sampling rate and DC-400 Hz online filtered. T1 anatomical scans (3-dimensional magnetization-prepared rapid gradient-echo sequences) were collected for patient-specific source localization of MEG activity (eMethods in the Supplement).

#### jamapsychiatry.com

## Magnetoencephalography Data Analysis

Magnetoencephalography data were analyzed with MAT-LAB using the open-source Fieldtrip Toolbox.<sup>45</sup> Preprocessing included correct trials only with nonoverlapping 3.8second segments (1-second baseline), time locked to the onset of the visual grating. Line noise was attenuated with a discrete 50-Hz Fourier transform filter, and faulty sensors with large signal variance or flat signals were removed. Data were denoised relative to MEG reference channels and downsampled to 300 Hz. Artifact-free data were created by removing trials with excessive transient muscle activity,

F value

Gamma power:

main effect of group

Visual cortical areas of significant

## Figure 2. Sensor and Source-Power Magnetoencephalography (MEG) Data

A Sensor-level MEG data



B Beamformer-localized main group effect on gamma power



A, Sensor-level MEG data: left topographical distribution plot shows grand average-induced y power (n = 232) changes from baseline. with white dots marking the sensors for which the time frequency response (TFR) plot in the middle is plotted. In the TFR plot, the outlined (black box) window indicates the window of statistical testing for group differences in y power. The TFR plot shows evoked activity from stimulus onset (time zero) to approximately 250 milliseconds, from which latency-induced activity is shown up to 1500 milliseconds. Right topographical distribution plot shows F values of significant (marked with white dots) sensors showing a main group effect on y power. B,

Beamformer-localized main group effect on y power. Lighter-blue and light-orange values mark areas of significant effects uncorrected for multiple comparisons, whereas the darker colors display false discovery rate-corrected areas ( $\alpha$  = .05; 2-sided). C, Locations across visual cortical areas of significant  $\gamma$ activity from which virtual channel time-series MEG data were reconstructed. The 10 occipital regions of interest (ROIs) included 3 subregions covering the primary visual cortex. CAL indicates calcarine; CUN, cuneus; IOG, inferior occipital gyrus; MOG, middle occipital gyrus; SOG, superior occipital gyrus.

slow drift, or superconducting quantum interference device jumps using visual inspection, and independent component analysis-based removal of eye blink, eye movement, and electrocardiographic artifacts. Data were then submitted to time-frequency (TFR) analyses (1-90 Hz, stepsize 50 milliseconds, 450 milliseconds sliding-window fast-fourier transformed [FFT]; Hanning tapered), computed for planarorientation transformed MEG data.46

Whole-brain source estimation of y-band power (57-67 Hz) between 250 and 750 milliseconds was computed using the Dynamic Imaging of Coherent Sources beamforming approach<sup>47</sup> (eMethods in the Supplement). y-Band source data were statistically tested across groups to determine the location of main effects (Figure 2). These were then used to guide selection of the main regions of interest (ROIs) for more fine-grained virtual channel analyses (Figure 2 and Figure 3C) (eMethods in the Supplement). Virtual channel time series were used for the analysis of event-related fields (ERF), TFR, inter-trial phase coherence (ITPC),<sup>48</sup> baseline FFT, and Granger causality (GC).

Granger-causality estimates were computed using a nonparametric approach, including spectral density matrices estimated directly from FFT-data (250-750 milliseconds; DC-149 Hz; Hanning tapered; 5-Hz frequency smoothing; 1-Hz resolution; data zero-padded to 4 seconds), followed by matrix factorization and variance decomposition. Epochs were split into 2 × 250millisecond segments to increase trial numbers (see Michalareas et al<sup>32</sup>). The middle occipital gyrus and cuneus ROIs were not used in the GC analyses to minimize overlap between primary visual, dorsal, and ventral stream connectivity estimates. Grangercausality data from each pair were averaged over hemisphere to create 4 main ROI pairs for statistical testing. To determine the alterations in feedforward (FF) vs feedback (FB) GC activity, we also computed the directed asymmetry index (DAI; see Michalareas et al,<sup>32</sup> Bastos et al,<sup>49</sup> and eMethods in the Supplement).

Figure 3. Virtual Channel Time Frequency Response (TFR) and Intertrial Phase Coherence (ITPC) Analyses



A, Top 4 panels show per group the TFR, averaged over all virtual-channel regions of interest (ROIs) shown in Figure 2C. Bottom right panels: TFR plot with statistical results (nonparametric, Monte Carlo-based permutation independent *t* tests) of group differences in time-frequency clusters between 0 and 750 milliseconds, with significant clusters outlined and the remaining nonsignificant time-frequency bins masked out (opacity, 0.45). The line graph on the left shows the  $\gamma$  (57-67 Hz) response over time per group, with error bars

representing standard error of the mean. B, Top panels show the ITPC responses per group and bottom panels show the significant group differences (between 0-350 milliseconds), with significant time-frequency bins outlined. The line graph on the left shows  $\gamma$  (30-50 Hz) range ITPC responses per group, with error bars representing standard error of the mean. CHR-N indicates clinical high risk negative; CHR-P, clinical high risk positive; FEP, first-episode psychosis; HC, healthy control individuals.

## **Statistical Analysis**

Group differences in trial numbers, γ-band peak frequency, behavioral performance, demographic, and clinical data were assessed with 1-way Welch analysis of variance (ANOVA); 2-sided a level of .05. Brief Assessment of Cognition in Schizophrenia

jamapsychiatry.com

data were first *z*-normalized to the HC data. Bootstrapping (n = 1000) and Games-Howell correction were used to control type I errors in post hoc pairwise group comparisons.

Statistical testing of group differences in MEG virtualchannel data included nonparametric Monte-Carlo-based permutation (n = 2000) independent *F* test (main group effect) and post hoc *t* test statistics<sup>45</sup> for ERFs (0-750 milliseconds); TFRs and ITPC power (1-90 Hz, 0-750 milliseconds for TFR power, 0-350 milliseconds for ITPC, and dB change from a 500-millisecond baseline); baseline FFT spectra (1-90 Hz); and GC data. Type I errors were controlled by cluster statistics across time and/or frequency (eMethods in the Supplement). Finally, binary logistic regression and receiver operating characteristic curve (ROC) analyses were used to examine the association between MEG parameters and clinical outcomes in CHR-P participants (eMethods in the Supplement).

## Results

#### **Demographic Data**

The FEP group included significantly more men than the HC ( $\chi_1^2 = 5.8$ ; P = .02), CHR-N( $\chi_1^2 = 6.7$ ; P = .01), and CHR-P( $\chi_1^2 = 11.6$ , P = .001) groups (Table). The BACS composite score was significantly reduced in CHR-P participants compared with HC (-0.84; 95% CI, -1.43 to -0.25; P = .004). All clinical groups differed from HC in global assessment of functioning (GAF) scores (CHR-N, 17.7; 95% CI, 11.7 to 23.8; P < .001; CHR-P, 30.3; 95% CI, 26.3 to 34.2; P < .001; FEP, 46.6, 95% CI, 37.2 to 56.0; P < .001). Both CHR-P and CHR-N groups also differed from HC in global role and social functioning (CHR-N, -0.63; 95% CI, -0.28 to -0.99; P < .001; CHR-P, -1.35; 95% CI, -1.05 to -1.66; P < .001).

## **Follow-up Outcomes**

We examined persistence of APS up to 12 months in CHR-P participants who met APS criteria at baseline (n = 84). For 75 CHR-P participants, at least 1 follow-up assessment was available. Thirty-nine CHR-P participants continued to meet APS criteria (APS-persistent group) while 36 CHR-P participants were characterized by a remission of APS-criteria (eResults in the Supplement). Moreover, 9 of 119 CHR-P participants made a transition to psychosis (mean follow-up period, 17.3 months). Eight transitions occurred in the APS-persistent group.

#### **Task Performance**

The CHR-P group was characterized by reduced response accuracy (-4.2%; 95% CI, -7.6 to -0.7; P = .01), while the patients with FEP were significantly more variable in reaction times (RTs) (27 milliseconds; 95% CI, 2 to 53; P = .03) compared with HC (Table).

#### **Sensor-Level Analysis**

Modulation of spectral power was characterized by early evoked activity (<approximately 250 milliseconds), which is phase locked and time locked to the onset of the stimulus and sustained induced activity that represents non-phase-locked oscillations (>250 milliseconds) (Figure 2). Task-induced  $\gamma$  peak frequency across participants was approximately 62 Hz. A main group effect (cluster  $F_{3,228} = 341.7$ ; P < .001; 95% CI range, -0.0004 to 0.002) for 57- to 67-Hz power was found over occipital and parietal-temporal regions (Figure 2A), with no differences in any other frequency range. Post hoc test results revealed significantly increased  $\gamma$  power for CHR-N vs HC over

858 JAMA Psychiatry August 2020 Volume 77, Number 8

superior occipital-parietal regions (cluster  $t_{85} = 48.4$ ; P = .03; 95% CI range, 0.0147-0.0453) and significantly decreased  $\gamma$  power (cluster  $t_{73} = -50.7$ ; P = .02; 95% CI range = 0.0143-0.0257) over inferior occipital regions for FEP compared with HC (eFigure 1 in the Supplement).

## Virtual Channel Analyses: TFR and ITPC Analyses

A cluster of sustained  $\gamma$ -band power decreases across all visual cortex ROIs (Figure 3A) for the FEP group compared with HC (TFR cluster approximately 50-75 Hz; approximately 0-750 milliseconds; cluster  $t_{73} = -791.8$ ; P = .007; 95% CI range, 0.0033-0.0107) were observed in primary visual cortex as well as in ventral stream areas (eFigure 2A in the Supplement). The CHR-N and CHR-P groups did not show spectral power changes in any frequency range.

Differences in  $\beta/\gamma$ -band ITPC values were found for both CHR-P and FEP participants compared with HC (CHR-P: TFRcluster approximately 21-68 Hz; approximately 125-275 milliseconds; cluster  $t_{166} = -509.1$ ; P = .005; 95% CI range, 0.0022 to 0.0078; FEP: TFR-cluster approximately 11-57 Hz; approximately 75-325 milliseconds; cluster  $t_{73} = -633.1$ ; P = .002; 95% CI, 0.0018-0.0022) (Figure 3B) that involved primary visual as well as ventral stream regions and that extended to dorsal stream areas in the patients with FEP (eFigure 2B in the Supplement). The CHR-N group showed intact ITPC spectral power across all visual ROIs and frequencies.

## Behavioral and Magnetoencephalographical Parameters Associated With APS Persistence in the CHR-P Group

Intertrial phase coherence data (30-50 Hz; 125-200 milliseconds) from 10 occipital ROIs, accuracy, RTs, and RT variability were entered into a regression model to predict persistence of APS criteria in the CHR-P group. Only  $\gamma$ -band ITPC (30-50 Hz) activity contributed significantly to the model. Specifically, ITPC data from the left/right cuneus and left middle occipital gyrus ROIs led to a significant model ( $\chi_3^2$  = 14.4; *P* = .002) that explained 22.2% of the variance (Nagelkerke *R*<sup>2</sup> = 0.222). The associated ROC curve was also significant (**Figure 4**A: area under the curve, 0.728; 95% CI, 0.612-0.841; *P* = .001) (eMethods and eResults in the Supplement).

# Regions of Interest: Baseline Power Spectra and ERF Responses

No group differences in baseline spectral power (1-90 Hz) or ERF amplitudes were observed in any visual cortex ROI (eFigures 3 and 4 in the Supplement).

#### **GC Connectivity**

A main group effect was found for 2 connections in visual cortex (Figure 4B: calcarine [CAL] to superior occipital gyrus; approximately 50-77 Hz; cluster P = .004; 95% CI range, 0.0014-0.0066; inferior occipital gyrus [IOG] to CAL: approximately 1-14 Hz; cluster P = .02; 95% CI range, 0.0163-0.0237) and a fronto-occipital connection (medial-superior frontal [mSFG] to IOG: approximately 24-41 Hz; cluster P = .007; 95% CI range, 0.0033 to 0.0107). Post hoc comparisons revealed decreased connectivity in the FEP group in visual cortex (CAL to superior occipital gyrus: DAI = 0.04;  $t_{73} = -3.0$ ; P = .006; 95% CI

80

SOG

IOG

CAI

90

## Figure 4. Receiver Operating Characteristic (ROC) Curve Analysis and Granger Causality (GC) Functional Connectivity

A CAARMS persistence and ITPC values









A. On the right, ROC curve computed from prediction probabilities associated with a significant logistic regression model for predicting 12 months Comprehensive Assessment of At Risk Mental States (CAARMS; attenuated psychotic symptoms) persistence status from baseline magnetoencephalography (MEG) recordings of intertrial phase coherence (ITPC) of visual cortex responses (left and right cuneus and left middle occipital gyrus; locations shown in left panel). B, Results of cluster-based statistics on GC data showing range of significant effects in first-episode psychosis (FEP), clinical high-risk positive (CHR-P), and clinical high risk negative (CHR-N) groups, compared with healthy control individuals (HC). The main connections tested are plotted on a

smoothed surface of a standard Montreal Neurological Institute brain, with red lines representing increased and blue lines decreased GC values, compared with HC. For each significant connection, GC values are plotted across the frequency spectrum, separately per group (with error bars indicating standard error of the mean), and a horizontal line indicating the frequency range of significant group effects. The GC was computed for data between 250 to 750 milliseconds after stimulus onset. The directed asymmetry indices were all positive in the significant contrasts, indicating feed-forward flow of information between the nodes. AUC indicates area under curve.

range, 0.0026 to 0.0094; IOG to CAL: DAI = 0.11;  $t_{73}$ = -3.5; *P* = .004; 95% CI range, 0.0012-0.0068) but increased frontooccipital connectivity (mSFG-to-IOG connection: DAI = 0.11; *t*<sub>73</sub> = 4.5; *P* < .001; 95% CI range, -0.0004 to 0.002). Comparable long-range connectivity changes were seen in the CHR-P group (mSFG-to-IOG: DAI = 0.07;  $t_{166}$  = 3.19; P = .003; 95% CI range, 0.0028-0.0032). The CHR-N group showed decreased IOG-to-CAL connectivity (DAI = 0.11;  $t_{85}$  = -3.5; P = .002; 95% CI range, 0.0002-0.0038).

#### jamapsychiatry.com

#### Correlations

Correlations were tested using linear regression models ( $\alpha < .05$ ; 2-sided; 1000-sample bootstrapping), with occipital y power (57-67 Hz; 250-750 milliseconds) and occipital 30- to 50-Hz ITPC (125-200 milliseconds) as dependent variables. Across all groups, y-band power changes were positively correlated with ITPC values (unstandardized *B* = 0.077; 95% CI, 0.041-0.113; standardized  $\beta$  coefficient = 0.274;  $t_{228}$  = 4.3; P < .001) and RT variance (*B* = 0.003; 95% CI, 0.001-0.006; β = 0.257; *t*<sub>228</sub> = 2.7; *P* = .008), and negatively with RTs (*B* = -0.002; 95% CI, -0.004 to -0.001; β = -0.349;  $t_{228}$  = -3.6; *P* < .001), together explaining 13.2% of variance (*R*<sup>2</sup> = 0.132). Thirty- to 50-Hz ITPC was positively associated with accuracy (*B* = 0.041; 95% CI, 0.018-0.065; β = 0.198;  $t_{228}$  = 3.4; *P* = .001) and GAF scores (*B* = 0.036; 95% CI, 0.024-0.047; β = 0.347;  $t_{228}$  = 5.9; *P* < .001) but negatively correlated with occipital β-band (16-22 Hz) power (*B* = -0.301; 95% CI, -0.562 to -0.040; β = -0.128,  $t_{228}$  = -2.3; *P* = .02) and CAARMS severity (*B* = -0.025; 95% CI, -0.036 to -0.013; β = -0.281;  $t_{204}$  = -4.2; *P* < .001) and explained 28.7% of variance (*R*<sup>2</sup> = 0.287).

#### Local and Long-range Oscillations in CHR-P Subgroups

We examined differences between CHR-P subgroups (CAARMS n = 34; SPI-A n = 30; CAARMS/SPI-A n = 55) in MEG activity and behavioral and clinical parameters (eResults, eFigure 6, and eTables 1-3 in the Supplement). Only the combined CAARMS/SPI-A group showed a significant ITPC-deficit relative to HC (TF-cluster approximately 24-72 Hz; approximately 0-300 milliseconds; cluster P < .001; 95% CI range, -0.0004 to 0.002). The effect size (d = 1.20) was comparable with the FEP group (d = 0.93). The CHR-P groups showed no difference in spectral power, while CHR-P individuals with CAARMS and CAARMS/SPI-A criteria showed a selective deficit in long-range connectivity between frontal and occipital cortex (for mSFG-to-IOG connection, see eResults and eFigure 7 in the Supplement).

## Discussion

This study examined neural oscillations during visual processing with a state-of-the art MEG approach to investigate whether emerging psychosis is associated with aberrant oscillatory activity in visual cortex as well as the functional relevance of impaired neural oscillations. Specifically, our data highlight a reduction of phase locking of high-frequency oscillations, a measure of the variability of an ongoing oscillation across trials,<sup>48</sup> in visual cortices as well as impaired longrange connectivity in CHR-P participants. Importantly, ITPC deficits were also associated with persistent APS, providing important evidence for the role of high-frequency oscillations in clinical staging of emerging psychosis.

Further evidence for the functional relevance of  $\beta/\gamma$ band phase locking are significant correlations with RTs, severity of APS, and the combination of SPI-A/CAARMS criteria as well as GAF-scores across participants. In addition,  $\beta/\gamma$ band ITPC was associated with induced  $\gamma$ -band power, highlighting the importance of the integrity of early visual processing for large-scale cognition and functioning. These data are consistent with previous findings that have identified associations between compromised sensory processing, impaired functioning, and cognitive deficits in schizophrenia.<sup>50-52</sup>

Comparisons between FEP and CHR-P groups revealed overlapping and distinct oscillatory signatures. Induced  $\gamma$ -band oscillations were prominently impaired in the FEP group in visual areas, which was not observed in CHR-P participants. Both groups were characterized by impaired long-range connectiv-

ity between visual and frontal cortices while the FEP group also showed reduced visual cortex connectivity. An influential model in schizophrenia has been the disconnectivity hypothesis<sup>36</sup> as well as the notion of reduced cognitive control mediated by frontal cortices.<sup>53</sup> Our GC data are consistent with these hypotheses, suggesting a shared feature of both FEP and at-risk participants is the presence of impaired connectivity between sensory regions and frontal cortices.

Impairments in high-frequency oscillations showed a considerable degree of specificity. First, ITPC impairments were only found for activity in the  $\beta/\gamma$ -band range but not for lower frequencies. Together with the large reductions in induced  $\gamma$ -band activity in the FEP group, these data highlight the unique contribution of high-frequency oscillations toward circuit impairments in emerging psychosis. Second, the CHR-N group showed intact behavioral task parameters as well normal power and phase of high-frequency oscillations in visual cortices and long-range connectivity with only evidence for a circumscribed impairment in local connectivity in visual cortex.

Thus, EEG/MEG readouts could potentially inform clinical decision-making and search for novel treatment opportunities. The search for biomarkers that have prognostic utility and could guide treatments in emerging psychosis is an important objective of research.<sup>22</sup> This study highlights that impaired  $\gamma$ -band ITPC differentiates between CHR-P individuals who have a high likelihood of persistent APS and transition to psychosis vs CHR-P individuals who show more benign APS. On the other hand, reductions in induced  $\gamma$ -band power emerged as a specific signature of FEP, suggesting that impaired  $\gamma$ -band oscillations could serve as a biomarker for established psychosis that warrants more aggressive treatments, such as antipsychotic medications.

Our observations of increased variability in the timing of  $\beta/\gamma$ -band oscillations is consistent with formulations that have implicated aberrant glutamatergic and GABAergic neurotransmission as key mechanism for circuit dysfunctions in psychotic disorders.<sup>17,54,55</sup> Specifically, an increase in variability of neuronal responses can be elicited by N-methyl-Daspartate receptor hypofunction,<sup>56</sup> suggesting that elevated excitability in sensory regions during the early stages of psychosis may lead to favorable conditions for altered network dynamics to emerge. Moreover, deficits in high-frequency oscillations highlight the contribution of specific GABAergic interneurons, such as parvalbumin or somatostatinexpressing interneurons<sup>13,57</sup> that are impaired in visual areas in schizophrenia.58 In addition to the pharmacologic correction of aberrant circuit dynamics, it is also conceivable that interventions that improve the fidelity of sensory processing through cognitive remediation<sup>59</sup> or brain stimulation<sup>60</sup> could potentially prevent the progression of circuit dysfunctions from sensory areas to more extended networks.

#### Limitations

This study has several limitations. Although we can predict the persistence of subthreshold psychotic symptoms through MEG data in our CHR-P cohort, further follow-up data are required to test whether abnormalities in high-frequency oscillations can predict transition to psychosis as well as the persistence of Cognitive Disturbances and Cognitive-Perceptive Basic Symptoms criteria. Moreover, these data are only crosssectional. Accordingly, further studies are required to examine the longitudinal course of oscillatory deficits during emerging psychosis.

## Conclusions

In summary, this advanced MEG analysis provides, to our knowledge, the first comprehensive investigation into the oscillatory signatures during different stages of early psychosis. Specifically, we can show that the timing of high-frequency

#### **ARTICLE INFORMATION**

Accepted for Publication: January 28, 2020. Published Online: March 25, 2020. doi:10.1001/jamapsychiatry.2020.0284

**Open Access:** This is an open access article distributed under the terms of the CC-BY License. © 2020 Grent-'t-Jong T et al. *JAMA Psychiatry*.

**Correction:** This article was corrected on May 6, 2020, to update the Open Access status.

Author Affiliations: Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, Scotland (Grent-'t-Jong, Gross, Krishnadas, Uhlhaas); Department of Child and Adolescent Psychiatry. Charité Universitätsmedizin. Berlin. Germany (Grent-'t-Jong, Uhlhaas); Mental Health and Wellbeing, Institute of Health and Wellbeing, University of Glasgow, Glasgow, Scotland (Gajwani, Gumley); Institute for Biomagnetism and Biosignalanalysis, University of Muenster, Muenster, Germany (Gross); Department of Psychiatry, University of Edinburgh, Edinburgh, Scotland (Lawrie); Department of Clinical Psychology, University of Edinburgh, Edinburgh, Scotland (Schwannauer): Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich Heine University, üsseldorf, Bergische Landstrasse 2, 40629 Düsseldorf, Germany (Schultze-Lutter).

Author Contributions: Drs Grent-'t-Jong and Uhlhaas had full access to all the data in the study and take responsibility for the integrity and the accuracy of the data analysis.

Concept and design: Grent-'t-Jong, Gumley, Lawrie, Uhlhaas.

Acquisition, analysis, or interpretation of data: All authors.

*Drafting of the manuscript:* Grent-'t-Jong, Gumley, Krishnadas, Uhlhaas.

Critical revision of the manuscript for important intellectual content: Grent-'t-Jong, Gajwani, Gross, Gumley, Lawrie, Schwannauer, Schultze-Lutter, Uhlhaas.

Statistical analysis: Grent-'t-Jong, Uhlhaas. Obtained funding: Gumley, Lawrie, Uhlhaas. Administrative, technical, or material support: Gajwani, Gross, Gumley, Krishnadas, Schwannauer, Uhlhaas.

*Supervision:* Gajwani, Gross, Gumley, Lawrie, Schwannauer, Schultze-Lutter, Uhlhaas.

**Conflict of Interest Disclosures:** Dr Krishnadas reported grants from Neurosciences Foundation and NHSGGC R and D during the conduct of the study. Dr Lawrie reported grants and personal fees from Janssen, nonfinancial support from Otsuka,

jamapsychiatry.com

grants from Lundbeck, and personal fees from Sunovion outside the submitted work. Dr Uhlhaas reported research support from Lilly and Lundbeck outside the submitted work. No other disclosures were reported.

Funding/Support: The study was supported by the Medical Research Council (MR/L011689/1). Dr Krishnadas was supported by the Neurosciences Foundation.

Role of the Funder/Sponsor: The Medical Research Council had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Frances Crabbe. MSc. Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, Scotland for help in the acquisition of MEG/ MRI-data. The investigators also acknowledge the support of the Scottish Mental Health Research Network (http://www.smhrn.org.uk), now called the NHS Research Scotland Mental Health Network (http://www.nhsresearchscotland.org.uk/researchareas/mental-health), for providing assistance with participant recruitment, interviews, and cognitive assessments. We thank both the participants and patients who took part in the study and the research assistants of the YouR-study for supporting the recruitment and assessment of CHR participants.

#### REFERENCES

1. Gray CM, König P, Engel AK, Singer W. Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties. *Nature*. 1989;338(6213): 334-337. doi:10.1038/338334a0

 Womelsdorf T, Fries P, Mitra PP, Desimone R. Gamma-band synchronization in visual cortex predicts speed of change detection. *Nature*. 2006; 439(7077):733-736. doi:10.1038/nature04258
 Kim H, Ährlund-Richter S, Wang X, Deisseroth K, Carlén M. Prefrontal parvalbumin neurons in control of attention. *Cell*. 2016;164(1-2):208-218. doi:10.1016/j.cell.2015.11.038

4. Uhlhaas PJ, Singer W. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. *Neuron*. 2006;52(1):155-168. doi:10.1016/j.neuron.2006.09.020

5. Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW. Abnormal

oscillations in visual cortices is the first impairment to emerge in CHR-P participants in combination with abnormal longrange connectivity. Patients with FEP were characterized by a pronounced reduction in the power of induced  $\gamma$ -band oscillations in combination with reduced  $\beta/\gamma$ -band ITPC as well as local and long-range connectivity. Importantly, impaired  $\gamma$ -band IPTC-values were associated with the persistence of subthreshold psychotic experiences, suggesting that  $\gamma$ -band oscillations could constitute a possible biomarker for clinical staging of emerging psychosis. Future studies and preclinical research should therefore focus on the circuit-mechanisms mediating precise coordinated neural responses that could offer targets for preventive approaches.

neural synchrony in schizophrenia. *J Neurosci*. 2003;23(19):7407-7411. doi:10.1523/JNEUROSCI.23-19-07407.2003

**6**. Kwon JS, O'Donnell BF, Wallenstein GV, et al. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. *Arch Gen Psychiatry*. 1999;56(11):1001-1005. doi:10.1001/archpsyc. 56.11.1001

7. Grent-'t-Jong T, Rivolta D, Sauer A, et al. MEG-measured visually induced gamma-band oscillations in chronic schizophrenia: Evidence for impaired generation of rhythmic activity in ventral stream regions. *Schizophr Res.* 2016;176(2-3):177-185. doi:10.1016/j.schres.2016.06.003

8. Hamm JP, Gilmore CS, Picchetti NA, Sponheim SR, Clementz BA. Abnormalities of neuronal oscillations and temporal integration to low- and high-frequency auditory stimulation in schizophrenia. *Biol Psychiatry*. 2011;69(10):989-996. doi:10.1016/j.biopsych.2010.11.021

**9**. Ryman SG, Cavanagh JF, Wertz CJ, et al. Impaired midline theta power and connectivity during proactive cognitive control in schizophrenia. *Biol Psychiatry*. 2018;84(9):675-683. doi:10.1016/j. biopsych.2018.04.021

**10**. Uhlhaas PJ, Singer W. Neuronal dynamics and neuropsychiatric disorders: toward a translational paradigm for dysfunctional large-scale networks. *Neuron*. 2012;75(6):963-980. doi:10.1016/j.neuron. 2012.09.004

**11.** Lisman J. Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia? *Curr Opin Neurobiol.* 2012;22(3): 537-544. doi:10.1016/j.conb.2011.10.018

**12**. Börgers C, Kopell N. Synchronization in networks of excitatory and inhibitory neurons with sparse, random connectivity. *Neural Comput.* 2003; 15(3):509-538. doi:10.1162/089976603321192059

13. Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. *Nature*. 2009;459 (7247):698-702. doi:10.1038/nature07991

 Womelsdorf T, Valiante TA, Sahin NT, Miller KJ, Tiesinga P. Dynamic circuit motifs underlying rhythmic gain control, gating and integration. *Nat Neurosci.* 2014;17(8):1031-1039. doi:10.1038/nn.3764
 Wang XJ. Neurophysiological and

computational principles of cortical rhythms in cognition. *Physiol Rev.* 2010;90(3):1195-1268. doi: 10.1152/physrev.00035.2008

**16**. Pocklington AJ, Rees E, Walters JT, et al. Novel findings from CNVs implicate inhibitory and excitatory signaling complexes in schizophrenia.

### *Neuron*. 2015;86(5):1203-1214. doi:10.1016/j. neuron.2015.04.022

 Lewis DA, Curley AA, Glausier JR, Volk DW.
 Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. *Trends Neurosci*. 2012;35(1):57-67. doi:10.1016/j.tins.2011.10.004
 Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. *Neuropsychopharmacology*. 2001; 25(1):1-27. doi:10.1016/S0893-133X(01)00225-1

 Kegeles LS, Mao X, Stanford AD, et al. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012;69(5): 449-459. doi:10.1001/archgenpsychiatry.2011.1519
 Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry.2013;70 (1):107-120. doi:10.1001/jamapsychiatry.2013.269
 Heinssen R, Insel TR. Prevention of mental disorders. Annu Rev Clin Psychol. 2012;8:269-289. doi:10.1146/annurev-clinpsy-032511-143146

22. McGorry P, Keshavan M, Goldstone S, et al. Biomarkers and clinical staging in psychiatry. *World Psychiatry*. 2014;13(3):211-223. doi:10.1002/wps.20144
23. Tada M, Nagai T, Kirihara K, et al. Differential alterations of auditory gamma oscillatory responses between pre-onset high-risk individuals and first-episode schizophrenia. *Cereb Cortex*. 2016;26 (3):1027-1035. doi:10.1093/cercor/bhu278

24. Perez VB, Roach BJ, Woods SW, et al. Early auditory gamma-band responses in patients at clinical high risk for schizophrenia. *Suppl Clin Neurophysiol*. 2013;62:147-162. doi:10.1016/B978-0-7020-5307-8.00010-7

**25**. Muthukumaraswamy SD, Singh KD. Visual gamma oscillations: the effects of stimulus type, visual field coverage and stimulus motion on MEG and EEG recordings. *Neuroimage*. 2013;69:223-230. doi:10.1016/j.neuroimage.2012.12.038

26. Siems M, Pape AA, Hipp JF, Siegel M. Measuring the cortical correlation structure of spontaneous oscillatory activity with EEG and MEG. *Neuroimage*. 2016;129:345-355. doi:10.1016/j. neuroimage.2016.01.055

27. Brookes MJ, Woolrich M, Luckhoo H, et al. Investigating the electrophysiological basis of resting state networks using magnetoencephalography. *Proc Natl Acad Sci U S A*. 2011;108(40): 16783-16788. doi:10.1073/pnas.1112685108
28. McGhie A, Chapman J. Disorders of attention

and perception in early schizophrenia. *Br J Med Psychol*. 1961;34:103-116. doi:10.1111/j.2044-8341.1961. tb00936.x

**29.** Uhlhaas PJ, Mishara AL. Perceptual anomalies in schizophrenia: integrating phenomenology and cognitive neuroscience. *Schizophr Bull*. 2007;33(1): 142-156. doi:10.1093/schbul/sbl047

**30**. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. *Arch Gen Psychiatry*. 2001; 58(2):158-164. doi:10.1001/archpsyc.58.2.158

**31**. Fries P, Neuenschwander S, Engel AK, Goebel R, Singer W. Rapid feature selective neuronal synchronization through correlated latency shifting. *Nat Neurosci*. 2001;4(2):194-200. doi:10. 1038/84032

**32**. Michalareas G, Vezoli J, van Pelt S, Schoffelen JM, Kennedy H, Fries P. Alpha-beta and gamma rhythms subserve feedback and feedforward

influences among human visual cortical areas. Neuron. 2016;89(2):384-397. doi:10.1016/j.neuron. 2015.12.018

**33**. Rutigliano G, Valmaggia L, Landi P, et al. Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. *J Affect Disord*. 2016;203:101-110. doi:10.1016/j.jad.2016.05.053

34. Lee TY, Shin YS, Shin NY, et al. Neurocognitive function as a possible marker for remission from clinical high risk for psychosis. *Schizophr Res.* 2014; 153(1-3):48-53. doi:10.1016/j.schres.2014.01.018
35. Friston KJ, Frith CD. Schizophrenia:

a disconnection syndrome? *Clin Neurosci*. 1995;3 (2):89-97.

**36.** Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. *Schizophr Bull*. 2009;35(3):509-527. doi:10.1093/ schbul/sbn176

**37**. Uhlhaas PJ, Gajwani R, Gross J, Gumley AI, Lawrie SM, Schwannauer M. The Youth Mental Health Risk and Resilience Study (YouR-Study). *BMC Psychiatry*. 2017;17(1):43. doi:10.1186/s12888-017-1206-5

**38**. Grent-'t-Jong T, Rivolta D, Gross J, et al. Acute ketamine dysregulates task-related gamma-band oscillations in thalamo-cortical circuits in schizophrenia. *Brain*. 2018;141(8):2511-2526. doi:10. 1093/brain/awy175

**39**. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. *Aust N Z J Psychiatry*. 2005;39(11-12):964-971. doi:10.1080/j. 1440-1614.2005.01714.x

**40**. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter K. *Schizophrenia Proneness Instrument, Adult Version. (SPI-A)*. Giovanni Fioriti Editore; 2007.

**41**. First MB, Spitzer R.*Structured Clinical Interview* for DSM IV Axis I Disorders—Patient Edition (SCID-I/P Version 2.0). Biometrics Research Department, New York State Psychiatric Institute; 1995.

**42**. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261

**43.** Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. *Schizophr Res.* 2004;68(2-3):283-297. doi: 10.1016/j.schres.2003.09.011

**44**. Hoogenboom N, Schoffelen JM, Oostenveld R, Parkes LM, Fries P. Localizing human visual gamma-band activity in frequency, time and space. *Neuroimage*. 2006;29(3):764-773. doi:10.1016/j. neuroimage.2005.08.043

**45**. Oostenveld R, Fries P, Maris E, Schoffelen JM. FieldTrip: open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data. *Comput Intell Neurosci*. 2011;2011:156869. doi:10.1155/2011/156869

**46**. Bastiaansen MC, Knösche TR. Tangential derivative mapping of axial MEG applied to event-related desynchronization research. *Clin Neurophysiol*. 2000;111(7):1300-1305. doi:10.1016/S1388-2457(00)00272-8

**47**. Gross J, Kujala J, Hamalainen M, Timmermann L, Schnitzler A, Salmelin R. Dynamic imaging of

coherent sources: Studying neural interactions in the human brain. *Proc Natl Acad Sci U S A*. 2001;98 (2):694-699. doi:10.1073/pnas.98.2.694

**48**. Tallon-Baudry C, Bertrand O, Delpuech C, Pernier J. Stimulus specificity of phase-locked and non-phase-locked 40 Hz visual responses in human. *J Neurosci*. 1996;16(13):4240-4249. doi:10. 1523/JNEUROSCI.16-13-04240.1996

49. Bastos AM, Vezoli J, Bosman CA, et al. Visual areas exert feedforward and feedback influences through distinct frequency channels. *Neuron*. 2015; 85(2):390-401. doi:10.1016/j.neuron.2014.12.018
50. Dias EC, Butler PD, Hoptman MJ, Javitt DC. Early sensory contributions to contextual encoding deficits in schizophrenia. *Arch Gen Psychiatry*. 2011;68(7): 654-664. doi:10.1001/archgenpsychiatry.2011.17
51. Haenschel C, Bittner RA, Haertling F, et al. Contribution of impaired early-stage visual processing to working memory dysfunction in adolescents with schizophrenia: a study with event-related potentials and functional magnetic resonance imaging. *Arch Gen Psychiatry*. 2007;64 (11):1229-1240. doi:10.1001/archpsyc.64.11.1229

**52.** Sergi MJ, Rassovsky Y, Nuechterlein KH, Green MF. Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. *Am J Psychiatry*. 2006;163(3):448-454. doi:10.1176/appi.ajp.163.3.448

**53.** Fornito A, Yoon J, Zalesky A, Bullmore ET, Carter CS. General and specific functional connectivity disturbances in first-episode schizophrenia during cognitive control performance. *Biol Psychiatry*. 2011;70(1):64-72. doi: 10.1016/j.biopsych.2011.02.019

**54**. Murray JD, Anticevic A, Gancsos M, et al. Linking microcircuit dysfunction to cognitive impairment: effects of disinhibition associated with schizophrenia in a cortical working memory model. *Cereb Cortex*. 2014;24(4):859-872.

**55**. Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. *Trends Neurosci*. 2008;31(5):234-242. doi:10.1016/j.tins.2008.02.005

**56**. Saunders JA, Gandal MJ, Siegel SJ. NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia. *Neurobiol Dis.* 2012;46(1):93-100. doi:10.1016/j. nbd.2011.12.049

**57**. Veit J, Hakim R, Jadi MP, Sejnowski TJ, Adesnik H. Cortical gamma band synchronization through somatostatin interneurons. *Nat Neurosci*. 2017;20 (7):951-959. doi:10.1038/nn.4562

58. Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, Lewis DA. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. *Am J Psychiatry*. 2008;165(4):479-489. doi:10.1176/appi. ajp.2007.07081223

**59**. Fisher M, Loewy R, Hardy K, Schlosser D, Vinogradov S. Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia. *Annu Rev Clin Psychol*. 2013;9:435-463. doi:10.1146/annurev-clinpsy-032511-143134

**60**. Hadar R, Bikovski L, Soto-Montenegro ML, et al. Early neuromodulation prevents the development of brain and behavioral abnormalities in a rodent model of schizophrenia. *Mol Psychiatry*. 2018;23(4):943-951. doi:10.1038/mp.2017.52